实用老年医学 ›› 2021, Vol. 35 ›› Issue (8): 875-878.doi: 10.3969/j.issn.1003-9198.2021.08.023
李芳玲, 张魏嘉, 熊晶
收稿日期:2020-09-18
出版日期:2021-08-20
发布日期:2021-08-30
通讯作者:
熊晶,Email: 625906385@qq.com
Received:2020-09-18
Online:2021-08-20
Published:2021-08-30
中图分类号:
李芳玲, 张魏嘉, 熊晶. 脑脊液和血液中S100B蛋白在阿尔茨海默病中的作用[J]. 实用老年医学, 2021, 35(8): 875-878.
| [1] A global assessment of dementia, now and in the future[J]. Lancet, 2015, 386(9997): 931. [2] BO Z, WAN Y, MENG S S, et al. The temporal trend and distribution characteristics in mortality of Alzheimer’s disease and other forms of dementia in China: Based on the National Mortality Surveillance System (NMS) from 2009 to 2015[J]. PloS One, 2019, 14(1): 1-14. [3] LIVINGSTON G, SOMMERLAD A, ORGETA V, et al. Dementia prevention, intervention, and care[J]. The Lancet, 2017, 390(10113): 2673-2734. [4] ALBERT M S, DEKOSKY S T, DICKSON D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease[J]. Alzheimers Dement, 2011, 7(3): 270-279. [5] MOOREB W. A soluble protein characteristic of the nervous system[J]. Biochem Biophys Res Commun, 1965, 19(6): 739-744. [6] STREITBURGER D P, ARELIN K, KRATZSCH J, et al. Validating serum S100B and neuron-specific enolase as biomarkers for the human brain-a combined serum, gene expression and MRI study[J]. PLoS One, 2012, 7(8): 1-8. [7] LAM V, ALBRECHT M A, TAKECHI R, et al. The serum concentration of the calcium binding protein S100B is positively associated with cognitive performance in older adults[J]. Front Aging Neurosci, 2013, 5: 16. [8] BAECKER J, WARTCHOW K, SEHM T, et al. Treatment with the neurotrophic protein S100B increases synaptogenesis after traumatic brain injury[J]. J Neurotrauma, 2020, 37(8): 1097-1107. [9] HUANG L, ZHANG L, LIU Z, et al. Pentamidine protects mice from cecal ligation and puncture-induced brain damage via inhibiting S100B/RAGE/NF-κB[J]. Biochem Biophys Res Communi, 2019, 517(2): 221-226. [10] WARTCHOW K M, TRAMONTNA A C, DA SOUZA D F, et al. Insulin stimulates S100B secretion and these proteins antagonistically modulate brain glucose metabolism[J]. Neurochem Res, 2016, 41(6): 1420-1429. [11] DE SOUZA D F, WARTCHOW K, HANSEN F, et al. Interleukin-6-induced S100B secretion is inhibited by haloperidol and risperidone[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2013, 43:14-22. [12] BELLAVER B, SOUZA D G, SOUZA D O, et al. Hippocampal astrocyte cultures from adult and aged rats reproduce changes in glial functionality observed in the aging brain[J]. Mol Neurobiol, 2017, 54(4): 2969-2985. [13] DE SOUZA D F, LEITE M C, QUINCOZES-SANTOS A, et al. S100B secretion is stimulated by IL-1β in glial cultures and hippocampal slices of rats: Likely involvement of MAPK pathway[J]. J Neuroimmunol, 2008, 206(1): 52-57. [14] GERLACH R, DEMEL G, KONIGH G, et al. Active secretion of S100B from astrocytes during metabolic stress[J]. Neuroscience, 2006, 141(4): 1697-1701. [15] STEINER J, BERNSTEIN H G, BIELAU H, et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain[J]. BMC Neurosci, 2007, 8:2. [16] BIANCHI R, GIAMBANCO I, DONATO R. S100B/RAGE-dependent activation of microglia via NF-κB and AP-1[J]. Neurobiol Aging, 2010, 31(4): 665-677. [17] HUGHES C G, PATEL M B, BRUMMEL N E, et al. Relationships between markers of neurologic and endothelial injury during critical illness and long-term cognitive impairment and disability[J]. Intensive Care Med, 2018, 44(3): 345-355. [18] GRIFFIN W S, STANLEY L C, LING C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease[J]. Proc Natl Acad Sci U S A, 1989, 86(19): 7611-7615. [19] PETZOLD A, JENKINS R, WATT H C, et al. Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer’s disease[J]. Neurosci Lett, 2003, 336(3): 167-170. [20] COX S R, ALLERHAND M, RITCHIE S J, et al. Longitudinal serum S100beta and brain aging in the Lothian Birth Cohort 1936[J]. Neurobiol Aging, 2018, 69:274-282. [21] PESKIND E R, GRIFFIN W S, AKAMA K T, et al. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer’s disease[J]. Neurochem Int, 2001, 39(5/6): 409-413. [22] CHRISTL J, VERHULSDONK S, PESSANHA F, et al. Association of cerebrospinal fluid S100B protein with core biomarkers and cognitive deficits in prodromal and mild Alzheimer’s disease[J]. J Alzheimers Dis, 2019, 72(4): 1119-1127. [23] CHAVES M L, CAMOZZATO A L, FERREIRA E D, et al. Serum levels of S100B and NSE proteins in Alzheimer’s disease patients[J]. J Neuro Inflamm, 2010, 7(1): 6. [24] FULLER K N Z, MIRANDA E R, THYFAULT J P, et al. Metabolic derangements contribute to reduced sRAGE isoforms in subjects with Alzheimer’s disease[J]. Mediators of Inflamm, 2018, 2018: 2061376. [25] SHENG J G, MRAK R E, GRIFFIN W S. S100 beta protein expression in Alzheimer disease: potential role in the pathogenesis of neuritic plaques[J]. J Neurosci Res, 1994, 39(4): 398-404. [26] CHOW S K, YU D, MACDONALD C L, et al. Amyloid beta-peptide directly induces spontaneous calcium transients, delayed intercellular calcium waves and gliosis in rat cortical astrocytes[J]. ASN Neuro, 2010, 2(1): 15-23. [27] MRAK R E, SHENG J G, GRIFFIN W S. Correlation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer’s disease[J]. J Neuropathol Exp Neurol, 1996, 55(3): 273-279. [28] MORI T, KOYAMA N, ARENDASH G W, et al. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer’s disease[J]. Glia, 2010,58(3): 300-314. [29] YEH C, YEH S H, SHIE F, et al. Impaired cognition and cerebral glucose regulation are associated with astrocyte activation in the parenchyma of metabolically stressed APPswe/PS1dE9 mice[J]. Neurobiol Aging, 2015, 36(11): 2984-2994. [30] ANDERSON P J, WATTS H R, JEN S, et al. Differential effects of interleukin-1beta and S100B on amyloid precursor protein in rat retinal neurons[J]. Clin Ophthalmol, 2009, 3:235-242. [31] WINOCUR G, RODER J, LOBAUGH N. Learning and memory in S100-β transgenic mice: an analysis of impaired and preserved function[J]. Neurobiol Learn Mem, 2001, 75(2): 230-243. [32] LIU J, WANG H, ZHANG L, et al. S100B transgenic mice develop features of Parkinson’s disease[J]. Arch Med Res, 2011, 42(1): 1-7. [33] HAGMEYER S, ROMÃO M A, CRISTÓVÃO J S, et al. Distribution and relative abundance of S100 proteins in the brain of the APP23 Alzheimer’s disease model mice[J]. Front Neurosci, 2019, 13:640. [34] SHAPIRO L A, BIALOWAS-MCGOEY L A, WHITAKER-AZMITIA P M. Effects of S100B on serotonergic plasticity and neuroinflammation in the hippocampus in Down syndrome and Alzheimer’s disease: studies in an S100B overexpressing mouse model[J]. Cardiovas Psychitary Neurol, 2010, 2010: 153657. [35] MORI T, TOWN T, TAN J, et al. Arundic acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice[J]. J Pharmacol Expe Ther, 2006, 318(2): 571-578. [36] HARTMAN K G, MCKNIGHT L E, LIRIANO M A, et al. The evolution of S100B inhibitors for the treatment of malignant melanoma[J]. Future Med Chem, 2013, 5(1): 97-109. [37] CIRILLO C, CAPOCCIA E, IUVONE T, et al. S100B inhibitor pentamidine attenuates reactive gliosis and reduces neuronal loss in a mouse model of Alzheimer’s disease[J]. Biomed Res Int, 2015, 2015: 508342. |
| [1] | 孙丽, 尹卫红, 经俊, 钱夏丽. 亚麻醉剂量艾司氯胺酮对老年脊柱手术病人术后早期认知功能障碍的影响[J]. 实用老年医学, 2024, 38(10): 1039-1043. |
| [2] | 董丽华, 李加梅, 郑加平, 雷小晶. 血液生物标志物在阿尔茨海默病早期诊断中的研究进展[J]. 实用老年医学, 2023, 37(12): 1249-1254. |
| [3] | 张伟, 王蓉. 衰老作为神经退行性疾病危险因素的科学现状分析[J]. 实用老年医学, 2023, 37(10): 984-988. |
| [4] | 时建铨, 郑慧芬, 徐畅, 王变荣. 认知障碍简明评价量表与Addenbrooke认知评估量表Ⅲ诊断阿尔茨海默病的准确性比较[J]. 实用老年医学, 2023, 37(10): 1041-1043. |
| [5] | 阎子花, 杜静, 宋竹梅, 张兴梅, 张楠. 痴呆病人病感失认测评工具的研究进展[J]. 实用老年医学, 2023, 37(10): 1059-1063. |
| [6] | 王琳琳, 杨诗怡, 徐俊. 人工智能在阿尔茨海默病中的研究进展[J]. 实用老年医学, 2023, 37(9): 869-872. |
| [7] | 王敏, 郭文军, 汤忠泉, 赵晓敏, 欧婷, 李云涛. 听力障碍与阿尔茨海默病相关性的Meta分析[J]. 实用老年医学, 2023, 37(9): 915-919. |
| [8] | 段景宜, 刘静, 查玉航, 杨巧露, 何海洋, 马亚男, 高海英. 阿尔茨海默病医防融合模式的探索[J]. 实用老年医学, 2023, 37(8): 757-760. |
| [9] | 张绍敏, 吴锦晖. COVID-19与阿尔茨海默病的最新研究进展[J]. 实用老年医学, 2023, 37(5): 521-523. |
| [10] | 赵璨, 冯美江. 外泌体与阿尔茨海默病的研究进展[J]. 实用老年医学, 2023, 37(4): 335-338. |
| [11] | 朱贺, 殷实. 认知障碍与抑郁症关系的研究进展[J]. 实用老年医学, 2023, 37(3): 234-237. |
| [12] | 郭晓娟, 刘洁, 王瑾, 陆文惠, 高玲, 屈秋民. 西安地区阿尔茨海默病病人药物依从性调查及影响因素分析[J]. 实用老年医学, 2023, 37(1): 47-50. |
| [13] | 陈绍敏, 王英. 轻度认知功能障碍老年人阿尔茨海默病风险预测的研究进展[J]. 实用老年医学, 2021, 35(12): 1304-1308. |
| [14] | 陈心怡, 孙杨, 徐德恩. 阿尔茨海默病外周血液生物标志物的研究进展[J]. 实用老年医学, 2021, 35(10): 1076-1079. |
| [15] | 王桢, 冯美江. 阻塞性睡眠呼吸暂停低通气综合征和阿尔茨海默病相关性研究进展[J]. 实用老年医学, 2021, 35(8): 795-797. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
|
